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1 These authors contributed equally to this work.RAC1 regulates a diverse array of cellular events including migration and invasion. MicroRNAs (miR-
NAs) have a key role in the regulation of gene expression. In this study, we demonstrated that micr-
oRNA-142-3p (miR-142-3p) acted as a negative regulator of human RAC1. Overexpression of miR-
142-3p decreased RAC1 mRNA and protein levels. Moreover, the overexpression of miR-142-3p sup-
pressed, while blocking of miR-142-3p increased colony formation, migration and invasion in hepa-
tocellular carcinoma (HCC) cell lines (QGY-7703 and SMMC-7721). RAC1 overexpression without the
30untranslated region abolished the effect of miR-142-3p in the QGY-7703 and SMMC-7721 cells.
These results demonstrated that miR-142-3p directly and negatively regulates RAC1 in HCC cells,
which highlights the importance of miRNAs in tumorigenesis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RAC1 is a GTPase that regulates a diverse array of cellular
events, including the control of cell growth, cytoskeletal reorgani-
zation, migration and invasion in addition to the activation of pro-
tein kinases. RAC1 cycles between an active GTP-bound state and
inactive GDP-bound state, which is regulated by guanine nucleo-
tide exchange factors (GEFs) and GTPase-activating proteins
(GAPs). Numerous studies have implicated RAC1 in various cardio-
vascular pathologies, such as vascular smooth muscle proliferation,
cardiomyocyte hypertrophy and endothelial cell shape change, and
cancer pathologies including adhesion, migration, invasion and vir-
al infection [1]. In addition, many upstream regulatory proteins
have been reported to speciﬁcally activate RAC1 in membrane ruf-
ﬂe, which is sufﬁcient for insulin induction of glucose uptake intochemical Societies. Published by E
FP, enhanced green ﬂuores-
ydrogenase; HCC, hepatocel-
miRNA, microRNA; UTR,
ce Research Center and Basic
ng-Tai Road, Tianjin 300070,skeletal muscle cells [2]. RAC1, as an upstream regulatory protein,
can also activate many other molecules. For example, abnormally
high levels of RAC1 promote b-catenin nuclear localization and
TCF/LEF-mediated transcription in cancer cell lines [3]. However,
the relationship of microRNAs (miRNAs) and RAC1 is unknown.
MiRNAs are small, endogenous non-coding RNAs that have been
identiﬁed as post-transcriptional regulators of gene expression.
MiRNAs bind to the 30untranslated regions (30UTRs) of target
mRNAs, either preventing their translation or causing target degra-
dation [4,5]. Hepatocellular carcinoma (HCC) is a malignancy that
has high incidences of tumor recurrence and metastasis, and it is
a major health problem worldwide, ranking as the ﬁfth most com-
mon cancer in the world and the third most common cause of can-
cer-related deaths [6]. Although the oncogenic and tumor-
suppressive functions of several miRNAs have been characterized,
the role of miRNAs in mediating tumor metastasis has only been
recently addressed and still remains largely unexplored [7,8]. To
investigate if speciﬁc miRNAs directly regulated RAC1 protein lev-
els and function, we identiﬁed microRNA-142-3p (miR-142-3p) as
potentially regulating RAC1 expression by binding to the 30UTR of
RAC1. This study demonstrated that overexpression of miR-142-3p
reduced RAC1 mRNA and protein levels and inhibited RAC1 func-
tions including colony formation, migration and invasion in the
HCC cell lines, QGY-7703 and SMMC-7721.lsevier B.V. All rights reserved.
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2.1. miRNA target prediction
The putative targets of miRNA were predicted using the Target-
Scan, PicTar, and miRBase Targets algorithms.
2.2. Cell culture and transfection
QGY-7703 and SMMC-7721 cells were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bo-
vine serum, 100 IU/ml of penicillin and 100 lg/ml of streptomycin.
The cells were incubated at 37 C in a humidiﬁed chamber supple-
mented with 5% CO2. Transfection was performed with a Lipofect-
amine 2000 Reagent (Invitrogen, Carlsbad, CA), according to the
manufacturer’s protocol.
2.3. Clinical HCC specimen and RNA isolation
Paired samples of primary HCCs and corresponding adjacent li-
ver tissues from patients were obtained from the Tumor Bank
Facility of Tianjin Medical University Cancer Institute and the Na-
tional Foundation of Cancer Research (TBF of TMUCIH and NFCR)
with patients’ informed consent. Ethics approval was granted by
the Ethics Committee of Tianjin Medical University. RNA was ex-
tracted using the mirVana miRNA Isolation Kit (Ambion, Austin,
TX), according to the manufacturer’s protocol.
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
To detect the relative transcript levels of miR-142-3p and RAC1,
RT-PCR was performed [9]. Brieﬂy, a cDNA library was generated
through reverse transcription using M-MLV reverse transcriptase
(Promega, Madison, WI) with 5 lg of extracted RNA, and this cDNA
was used for the ampliﬁcation of RAC1 and b-actin. PCR was per-
formed under the following conditions: 94 C for 4 min followed
by 40 cycles of 94 C for 1 min, 56 C for 1 min and 72 C for 1 min.
The following PCR primers were used: RAC1 30UTR sense, 50-CGTGG
ATCCGTGTGTGTGATCAAAGGAC-30; RAC1 30UTR antisense, 50-CGGA
ATTCATGGCAGGTGTAAGAGAAAGG-30; b-actin sense, 50-CGTGA-
CATTAAGGAGAAGCTG-30; and b-actin antisense, 50-CTAGAAGC-
ATTT GCGGTGGAC-30. To detect the levels of mature miRNA, a
stem-loop RT-PCR assay was performed. Brieﬂy, 5 lg of total RNA
was reverse transcribed to cDNA with the following primers that
can fold into a stem-loop structure: miR-142-3p-RT, 50-GTCGTATCC
AGTGCAGGGTCCGAGGTGCACTGGATACGACTCCATAA-30; and U6-
RT, 50-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGA
CAAAA TATGGAAC-30. The following PCR primers were used: miR-
142-3p-Fwd, 50-TGCGGTGTAGTGTTTCCTACTT-30; U6-Fwd, 50-TGCG
GGTGCTCGCTTCGGCAGC-30, and a universal downstream reverse
primer, 50-CCAGTGCAGGGTCCGAGGT-30. The PCR cycleswere as fol-
lows: 94 C for 4 min followedby 40 cycles of 94 C for 30 s, 50 C for
30 s and 72 C for 30 s. The SYBR Premix Ex Taq Kit (TaKaRa, Madi-
son, WI) was used according to the manufacturer’s instructions,
and the RT-PCR was performed and analyzed by the 7300 RT-PCR
system (ABI). All primers were purchased from AuGCT Inc. (Beijing,
China).
2.5. Western blot
All proteins were resolved on a 10% SDS denatured polyacryl-
amide gel and were then transferred onto a nitrocellulose mem-
brane. Membranes were incubated with blocking buffer for 90 min
at room temperature and were then incubated with an anti-RAC1
antibody or anti-glyceraldehyde phosphate dehydrogenase (GAP-DH) antibody with Blotto overnight at 4 C. The membranes were
washed and incubated with a horseradish peroxidase (HRP)-conju-
gated secondary antibody. Protein expression was assessed by en-
hanced chemiluminescence and exposure to chemiluminescent
ﬁlm. Lab Works Image Acquisition and Analysis Software (UVP)
were used to quantify band intensities. Antibodies were purchased
from Tianjin Saier Biotech (Tianjin, China) and Sigma–Aldrich.
2.6. Fluorescent reporter assay
The enhanced green ﬂuorescence protein (EGFP) expression
vector, pcDNA3/EGFP, was constructed as previously described
[10]. The 30UTR of human RAC1 was ampliﬁed using PCR, and the
RAC1 putative 30UTR binding site was cloned downstream of an
EGFP reporter gene (pEGFP-RAC1-30UTR). The pEGFP-RAC1-30UTR
(200 ng), pDsRed2-N1 (RFP expression vector for normalization;
50 ng) (Clontech, Mountain View, CA) and pcDNA3/pri-142-3p
constructs were cotransfected into cells. The intensities of EGFP
and RFP ﬂuorescence were detected with the F-4500 Fluorescence
Spectrophotometer (Hitachi, Tokyo, Japan). The EGFP expression
was normalized to RFP expression for each sample.
2.7. Cell viability assay
Twenty-four hours after transfection, cells were seeded in 96-
well plates at either 3000 cells/well (QGY-7703 cells) or 5000 cells/
well (SMMC-7721 cells). The WST-1 assay (Roche, Indianapolis, IN)
was used to measure cell viability at 48 and 72 h after transfection.
The absorbance at 450 nmwas measured using a lQuant Universal
Microplate Spectrophotometer (BioTek, Winooski, VT).
2.8. Colony formation assay
After transfection, cells were counted and seeded (100 cells/
well) in 12-well plates (in triplicate). Fresh culture mediumwas re-
placed every 2 days. Colonies were counted only if they contained
more than 50 cells, and the number of colonies was counted either
7 days (QGY-7703 cells) or 14 days (SMMC-7721 cells) after seed-
ing. The cells were stained using crystal violet. The ability of colony
formation was calculated by the colony formation number.
2.9. In vitro migration and invasion assays
In vitro cell migration assays were performed using transwell
chambers (pore size of 8 lM; Costar, Corning, NY). Transfected
cells were resuspended in serum-free medium, and 200 ll of the
cell suspension (4  104 cells) was added to the upper chamber.
Complete mediumwas added to the bottom wells of the chambers.
For the screen, the cells that had not migrated after either 7 h
(QGY-7703 cells) or 18 h (SMMC-7721 cells) were removed from
the upper face of the ﬁlters using cotton swabs. After ﬁxation
and staining in a dye solution containing 0.1% crystal violet and
20% methanol, the cells that were adhered to the lower membrane
of the inserts were counted. Images of three different ﬁelds (5
magniﬁcation) were taken for each membrane, and the number
of migratory cells was counted. The mean of triplicate assays for
each experimental condition was used. Similar inserts coated with
either 4 mg/ml (QGY-7703 cells) or 2 mg/ml (SMMC-7721 cells)
Matrigel (Clontech, Mountain View, CA) were used to determine
the invasive potential of the cells that had not invaded after either
9 h (QGY-7703 cells) or 24 h (SMMC-7721 cells).
2.10. Immunohistochemistry
Immunohistochemistry (IHC) was performed according to the
methods described previously [11]. The sections were pretreated
1324 L. Wu et al. / FEBS Letters 585 (2011) 1322–1330with microwave, blocked, and incubated using polyclonal rabbit
anti-human RAC1 (Saierbio, China). Staining intensity was
assessed.
2.11. Statistical analysis
Data were expressed as means ± S.D. Statistical analyses were
performed using a paired t-test to compare data. A P-value less
than 0.05 are considered statistically signiﬁcant. One representa-
tive experiment is shown in duplicates or triplicates in the statisti-
cal analysis.
3. Results
3.1. miR-142-3p downregulates RAC1 expression by targeting the
30UTR of RAC1
To investigate the relationship betweenmiRNAs and RAC1, three
algorithm programs (PicTar, TargetScan Release 4.0 and miRBase
Targets) were used to predict miRNAs targeting the 30UTR of
RAC1. A putative binding site for miR-142-3p was found in the
30UTR of RAC1, and it was found to be conserved in human, mouse,
chicken and rat mRNA (Fig. 1A). To test if miR-142-3p was able to
directly bind to the RAC1 30UTR and repress RAC1, we constructedFig. 1. MiR-142-3p downregulates RAC1 expression by targeting the 30UTR of RAC1. For
experiments. (A) The RAC1 30UTR has a putative miR-142-3p binding site that is conser
(mid) and its target site (targets) in the 30UTR of RAC1 (top) are shown. The 30UTR mu
transfected with pri-miR-142-3p was decreased after 48 h (P < 0.01). And the intensity
(P < 0.02). (C) Pri-miR-142-3p and ASO-miR-142-3p had no effect on the intensity of EGan EGFP reporter vector (pcDNA3/EGFP-RAC1-30UTR) with the
putative RAC1 30UTR miR-142-3p binding sequence downstream
of the EGFP stop codon. QGY-7703 cells were cotransfected with
either pcDNA3/pri-miR-142-3p and control vector or antisense oli-
gonucleotide (ASO)-miR-142-3p oligonucleotides and ASO-NC
(negative control). pDsRed2-NI was also cotransfected for normali-
zation. The intensity of EGFP ﬂuorescence in cells transfected with
pcDNA3/Pri-miR-142-3p was signiﬁcantly reduced after 48 h when
compared to the control cells, and the intensity of EGFP ﬂuores-
cence in cells transfected with ASO-miR-142-3p was signiﬁcantly
increased after 48 h when compared to the control cells (Fig. 1B).
To determine the function of the miR-142-3p binding site, we con-
structed an additional EGFP reporter vector containing the RAC1
30UTR with a mutant miR-142-3p binding site. As a result,
pcDNA3/pri-miR-142-3p and ASO-miR-142-3p had no effect on
the intensity of EGFP ﬂuorescence in cells transfected with the
30UTR mutant vector (Fig. 1C). These results demonstrated that
RAC1 is a direct target of miR-142-3p. Furthermore, to determine
if miR-142-3p suppressed endogenous RAC1 through translational
repression, RAC1 protein levels were detected by Western blot
analysis. In QGY-7703 cells transfected with pcDNA3/pri-miR-
142-3p, the mature miR-142-3p level was signiﬁcantly increased
(Fig. 2A), and the RAC1 mRNA and protein levels were signiﬁcantly
reduced (Fig. 2B and C). In QGY-7703 cells transfected withall panels, one representative experiment is shown out of at least three performed
ved in human, mouse, chicken and rat mRNA. The predicted duplex of miR-142-3p
tation of RAC1 is shown (bottom). (B) The intensity of EGFP ﬂuorescence of cells
of EGFP ﬂuorescence of transfected with ASO-miR-142-3p was increased after 48 h
FP ﬂuorescence with the 30UTR mutant vector (P > 0.05).
Fig. 2. Ectopic expression of miR-142-3p downregulates RAC1 expression, and ASO-miR-142-3p upregulates RAC1 expression in QGY-7703 cells. (A) In QGY-7703 cells
transfected with pcDNA3/pri-miR-142-3p, the mature miR-142-3p level was signiﬁcantly increased, (B) but the RAC1 mRNA and (C) protein levels were signiﬁcantly reduced.
(D) In QGY-7703 cells transfected with ASO-miR-142-3p, the mature miR-142-3p level was signiﬁcantly reduced, (E) RAC1 mRNA and (F) protein levels were signiﬁcantly
increased.
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reduced (Fig. 2D), and the RAC1 mRNA and protein levels were sig-
niﬁcantly increased (Fig. 2E and F). Similar results were obtained in
HEK-293 cells (data not shown). These data suggested that miR-
142-3p negatively regulates endogenous RAC1 protein expression
through mRNA degradation and translational repression.
3.2. miR-142-3p does not affect cell viability but affects colony
formation in HCC cells
To determine if miR-142-3p affected cell viability and growth,
we transfected QGY-7703 cells with either pcDNA3/pri-miR-142-
3p or ASO-miR-142-3p, and we used aWST-1 assay to measure cell
viability. The WST-1 assay indicated that pri-miR-142-3p and ASO-
miR-142-3p did not signiﬁcantly inﬂuence QGY-7703 cell viability
at 48 and 72 h, as compared to the control vector or ASO-NC
(Fig. 3A). Similar results were found in the SMMC-7721 cell line
(Fig. 3B). The colony numbers in QGY-7703 and SMMC-7721 cells
transfected with pri-miR-142-3p were lower than the colony num-
ber in control cells. However, ASO-miR-142-3p increased the ability
of colony formation in QGY-7703 (Fig. 3C) and SMMC-7721 cells
(Fig. 3D). Overall, these results demonstrated that the alteration
ofmiR-142-3p levels does not affect cell viability in a short duration
but does regulate the capacity of cell proliferation in HCC cell lines.
3.3. miR-142-3p inhibits migration and invasion of HCC cells in vitro
Previous reports have indicated that RAC1 has an important role
in cell migration and invasion. Therefore, we tested if miR-142-3pby targeting RAC1 was associated with the migration and invasion
properties of HCC cells. Transwell assays without Matrigel demon-
strated that the overexpression of miR-142-3p reduced the migra-
tion of QGY-7703 cells by 32% (Fig. 4A) and SMMC-7721 cells by
66% (Fig. 4C) when compared to the migration of control cells. In
contrast, ASO-miR-142-3p increased the migration of QGY-7703
cells by 57% (Fig. 4A) and SMMC-7721 cells by 109% (Fig. 4C) when
compared with ASO-NC. Transwell assays with Matrigel were used
to demonstrate the affect of miR-142-3p on the invasive potential
of cells. The overexpression of miR-142-3p resulted in a 94% reduc-
tion in the invasive potential of QGY-7703 cells when compared to
the control cells, and cells transfected with ASO-miR-142-3p had
an 88% increase in the invasive potential (Fig. 4B). Similar results
were observed in SMMC-7721 cells (Fig. 4D). These data indicated
that miR-142-3p suppresses the migration and invasion of HCC
cells in vitro.
3.4. RAC1 promotes cell colony formation, migration and invasion
in vitro
Previous studies have shown that the upregulation of RAC1 is
an important feature of many transformed cells and that RAC1
functions as an oncogene [12]. To test if RAC1 regulated prolifera-
tion, migration and invasion of HCC cells through mediating miR-
142-3p, we constructed a pSilencer-shRAC1 plasmid to knockdown
RAC1 level and also used a pcDNA3/RAC1 vector (a RAC1 overex-
pression vector that has the RAC1 ORF without the 30UTR) to re-
verse the negative effects of miR-142-3p on RAC1 protein level
(Fig. 5A). RAC1 knockdown by pSilencer-shRAC1 did not affect cell
Fig. 3. High expression levels of miR-142-3p do not affect QGY-7703 cell and SMMC-7721 cells viability but can effect colony formation in vitro. (A) QGY-7703 cells were
cotransfected with either pri-miR-142-3p and control vector or ASO-miR-142-3p and ASO-NC. QGY-7703 cell viability was detected by the WST-1 assay at 48 and 72 h
(P > 0.05). (B) Similar results were obtained in SMMC-7721 cells. (C) QGY-7703 cells were cotransfected with either pri-miR-142-3p and control vector or ASO-miR-142-3p
and ASO-NC in 48-well plates. The cells were then seeded in 12-well plates. For the colony formation assay, the cells were stained with crystal violet. The representative
pictures of colonies are shown. The number of colonies was counted on the eighth day after seeding. (D) SMMC-7721 cells were cotransfected with either pri-miR-142-3p and
control vector or ASO-miR-142-3p and ASO-NC. The results were similar to results in QGY-7703 cells.
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formation rate, migration and invasion of QGY-7703 cells
(Fig. 5C, F and G). The effects of RAC1 ectopic expression on prolif-
eration, migration and invasion were evaluated by colony forma-
tion and a transwell assay. When QGY-7703 cells were
cotransfected with pcDNA3/Pri-miR-142-3p and pcDNA3/RAC1,
the inhibition of colony formation, migration and invasion causedby pcDNA3/miR-142-3p were reversed with the expression of
pcDNA3/RAC1 when compared to the control vector (Fig. 5C, D
and E). The overexpression of RAC1 using pcDNA3/RAC1 counter-
acted the effect of miR-142-3p on cell growth, migration and inva-
sion of QGY-7703 cells (Fig. 5C, D and E).
Together, these results provide further evidence that RAC1 is an
oncogene. Therefore, ectopic expression of RAC1 might rescue
Fig. 4. MiR-142-3p inhibits cell migration and invasion of QGY-7703 and SMMC-7721 cells in vitro. (A) Transwell migration assays were carried out with QGY-7703 cells
cotransfected with either miR-142-3p and control vector or ASO-miR-142-3p and ASO-NC. Representative images are shown at the top, and the quantiﬁcation of ﬁve
randomly selected ﬁelds is shown at the bottom. Transwell assays without Matrigel demonstrated that miR-142-3p signiﬁcantly inhibited migration of QGY-7703 cells when
compared to the control vector groups. (B) Transwell assays with Matrigel demonstrated that miR-142-3p signiﬁcantly inhibited invasion of QGY-7703 cells when compared
to the control vector groups. (C) Overexpression and knockdown of miR-142-3p in SMMC-7721 cells had similar migration results. (D) Overexpression and knockdown of
miR-142-3p in SMMC-7721 cells had similar invasion results.
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sion caused by miR-142-3p. The oncogenic role of RAC1 in liver
cancer could explain why overexpression of miR-142-3p inhibits
colony formation, migration and invasion of liver cancer cells.
3.5. Expression of RAC1 and miR-142-3p in hepatoma and normal
tissues
To detect the expression of miR-142-3p in human hepatoma tis-
sue, the stem-loop quantitative RT-PCR assay was performed with
11 tissue pairs of hepatoma and adjacent normal tissues. After nor-
malization to the U6 control, miR-142-3p was expressed at signif-
icantly lower levels in tumor tissues when compared to the
corresponding non-tumor tissues. Overall, the miR-142-3p expres-
sion in the tumor samples was signiﬁcantly lower than that in the
non-tumor tissue samples (Fig. 6A). After normalization to the b-
actin control, RAC1 was expressed at signiﬁcantly higher levels in
the tumor tissues when compared to the corresponding normal tis-
sues (Fig. 6B). In order to study the correlation of RAC1 and HCC,we also used immunohistochemistry to determine the expression
of RAC1 in normal liver tissue (n = 11) and HCC tissue (n = 11).
The expression of RAC1 in HCCs was signiﬁcantly higher compared
to normal liver tissue (Fig. 6C). Thus, these results further sup-
ported that miR-142-3p negatively regulates RAC1.
4. Discussion
Invasion and metastasis, two of the most important hallmarks
of cancer, are the leading lethal factors in malignant cancer, espe-
cially for HCC [13]. Metastasis is the major contributing factor in
liver failure, tumor recurrence and death in HCC patients. Unfortu-
nately, no promising curative therapy for HCC metastasis is yet
available. Therefore, treatment for HCC still remains a formidable
challenge [14]. Many studies have demonstrated that the RhoGT-
Pase pathway has important roles in mediating HCC metastasis
based on the function of the pathway in regulating cell cytoskeletal
reorganization. Cell morphology and migration are regulated by
members of the Rho family of small GTPases, including Rho, Rac1
Fig. 5. RAC1 promotes HCC cell colony formation, migration and invasion in vitro. (A) Western blot analysis showed that ectopic expression of RAC1 without a 30UTR rescued
the decreased RAC1 protein caused by miR-142-3p or the pSilencer-shRAC1 vector. (B) The WST-1 assay indicated that RAC1 overexpression and RAC1 knockdown did not
inﬂuence QGY-7703 cell growth or viability. (C) The colony formation assay revealed that the average colony formation number was rescued by the expression of RAC1
without a 30UTR, and the average colony formation number was decreased by RAC1 knockdown. (D) Ectopic expression of RAC1 without a 30UTR rescued QGY-7703 cell
migration. (E) Ectopic expression of RAC1 without a 30UTR rescued QGY-7703 cell invasion. (F) RAC1 knockdown decreased QGY-7703 cell migration. (G) RAC1 knockdown
decreased QGY-7703 cell invasion.
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such as endothelial cells, and it has a role in vascular tube forma-
tion and lumen formation in vitro [16,17].
Recently, increasing evidence has shown dysregulation of miR-
NAs in various types of cancers [18–20]. Identiﬁcation of cancer-
speciﬁc miRNAs and their targets is critical for understanding their
role in tumorigenesis and might be important for deﬁning novel
therapeutic targets [21–23]. Decreased expression of miR-199a-
5p contributes to increased cell invasion hepatocellular via the
functional deregulation of DDR1 activity in HCC [24]. Members of
the let-7 miRNA family can negatively regulate all three members
of the RAS oncogene family [25], and miR-15a/miR-16-1 can target
and regulate BCL2 in B-cell CLL cells [26]. Together, these ﬁndings
suggest that miRNA dysregulation may be involved in cancer path-
ogenesis. Prior to this study, however, it was unclear which miRNA
regulated RAC1.
In this study, we focused on the role of miR-142-3p targeting
RAC1 in human HCC cells. In a bioinformatics analysis, RAC1 tran-
script was predicted to have a miR-142-3p binding site (Fig. 1A).
Experimental evidence indicated that miR-142-3p was a target ofRAC1. First, the ability of miR-142-3p to regulate RAC1 expression
was likely direct because it bound to the 30UTR of RAC1 mRNA
complementarily to the miR-142-3p seed region. Second, the EGFP
ﬂuorescence intensity of EGFP-RAC1-30UTR was speciﬁcally
responsive to miR-142-3p overexpression (Fig. 1B). Third, muta-
tion of the miR-142-3p binding site abolished the effect of miR-
142-3p on the regulation of EGFP ﬂuorescence intensity (Fig. 1C).
Fourth, we observed an inverse correlation between the expression
of miR-142-3p and RAC1 in tumor tissues and corresponding nor-
mal liver tissues by RT-PCR (Fig. 6). Finally, endogenous RAC1
expression, both mRNA and protein, was decreased in QGY-7703
cells transfected with pri-miR-142-3p but was increased in QGY-
7703 cells transfected with ASO-miR-142-3p (Fig. 2). These results
suggested that miR-142-3p regulates RAC1 protein expression. It
has been presumed that downregulated miRNAs in cancers may
normally function as tumor suppressor genes. Therefore, we
hypothesized that miR-142-3p is a growth inhibition factor in
HCC. Because miR-142-3p expression is decreased in cancer tis-
sues, we used the WST-1 assay to evaluate the effect of miR-142-
3p overexpression on cell viability. The cell viability of QGY-7703
Fig. 6. Differential expression of miR-142-3p and RAC1 in liver tissues. (A) The relative expression level of (A) miR-142-3p and (B) RAC1 in the 11 liver tissue pairs including
HCC tissues (Ca) and matched normal tissues (N) was detected by quantitative RT-PCR. (C) Expression of RAC1 in liver cancer tissue and normal liver tissues by
immunohistochemistry.
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pression vector (pri-miR–142-3p) was not signiﬁcantly inﬂuenced
when compared to control cells (Fig. 3). Moreover, ASO-miR-142-
3p did not inﬂuence cell viability when compared to ASO-NC
(Fig. 3). In the colony formation assay, however, we observed that
the colony formation activity of QGY-7703 and SMMC-7721 cells
transfected with pri-miR-142-3p was signiﬁcantly inhibited
(Fig. 4). Furthermore, the colony formation activity of QGY-7703
and SMMC-7721 cells transfected with ASO-miR-142-3p was sig-
niﬁcantly increased (Fig. 4).
To test if miR-142-3p inhibited QGY-7703 cell colony formation
through the RAC1 protein, RAC1 was ectopically expressed in the
presence of miR-142-3p. Ectopic expression of RAC1 without the
30UTR rescued the inhibition of colony formation in QGY-7703 cells
caused by miR-142-3p. Moreover, RAC1 knockdown inhibited col-
ony formation in the QGY-7703 cells. These results were in accor-
dance with RAC1 function. Inhibition of RAC1 activity by the
pharmacologic inhibitor, NSC23766, has been shown to suppress
cell growth in a panel of human breast cancer cell lines [27] be-
cause RAC1 is critical for cell growth, migration and invasion.
Moreover, Type I PIPK-alpha regulates directed cell migration by
modulating RAC1 plasma membrane targeting and activation
[28]. PED interacts with RAC1 and regulates cell migration and
invasion processes in human non-small cell lung cancer cells
[29]. When QGY-7703 and SMMC-7721 cells were cotransfected
with either pri-miR-142-3p and control vector or ASO-miR-142-
3p and ASO-NC, transwell assays lacking Matrigel demonstrated
that miR-142-3p signiﬁcantly inhibited the migration of QGY-
7703 and SMMC-7721 cells when compared to control cells. Simi-
larly, transwell assays with Matrigel showed that the invasive
capacities were dramatically induced in QGY-7703 and SMMC-
7721 cells transfected with when compared to the control cells.
To determine if RAC1 functioned downstream of miR-142-3p, res-
cue and knockdown experiments were performed in QGY-7703
cells, followed by migration and invasion assays. Ectopic expres-
sion of RAC1 rescued the inhibition of migration and invasion in
QGY-7703 cells caused by miR-142-3p. Furthermore, RAC1
knockdown signiﬁcantly inhibited QGY-7703 cell migration andinvasion. Together, these results demonstrated that miR-142-3p
reduces RAC1 expression levels and decreases colony formation,
migration and invasion of cells.
In summary, we demonstrated that miR-142-3p expression is
downregulated in HCC tissues and that miR-142-3p inhibits HCC
cell colony formation, migration and invasion by targeting RAC1.
These results suggest that miR-142-3p could have an important
role in tumorigenesis by regulating RAC1.
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